- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00352742
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib
Study Overview
Detailed Description
Multiple myeloma is a bone marrow based malignancy of plasma cells that is highly treatable but rarely curable. Angiogenesis, defined as the growth of new blood vessels from pre-existing vessels, is a requirement for the growth of nearly all tumors. An increase in bone marrow angiogenesis is present in Multiple Myeloma and correlates with disease progression. Several new therapies that target angiogenic pathways have shown clinical efficacy. ATN-224 is a small molecule that has been shown in pre-clinical studies to be antiangiogenic.
Using one agent to overcome resistance of another agent is a treatment regimen used in oncology. A preclinical study with the combination of ATN-224 and bortezomib shows that the combination is more effective than either single agent in a bortezomib resistant cell line.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Fresno, California, United States, 93720
- Hematolgy-Oncology Medical Group of Fresno, Inc.
-
West Hollywood, California, United States, 90069
- Institute for Myeloma and Bone Cancer Research
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Center For Cancer And Blood Disorders
-
-
Montana
-
Billings, Montana, United States, 59101
- Billings Clinic
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08903
- The Cancer Institute of New Jersey
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY Downstate
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Texas
-
Dallas, Texas, United States, 75246
- Mary Crowley Medical Research Center
-
Tyler, Texas, United States, 75702
- Tyler Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed multiple myeloma that has been treated with at least one different prior anti-myeloma regimens including one with bortezomib and is currently showing evidence of progressive disease
- Myeloma that is refractory to the most recent bortezomib-containing regimen as demonstrated by progressive disease while on bortezomib or that relapsed within 12 weeks of the last dose of bortezomib either as a single agent or in combination with other agents
- Measurable disease defined as a serum M-protein concentration on electrophoresis ≥1 g/dL of IgG myeloma or ≥0.5 g/dL of IgA myeloma or IgM myeloma or urinary excretion of monoclonal light chain ≥200 mg/24 hours
- Age >18 years
- Life expectancy of greater than 3 months
- ECOG performance status <2 (Karnofsky >60%; see Appendix A)
Adequate organ and marrow function as defined below:
- absolute neutrophil count ≥1,000/uL
- platelets ≥75,000/uL
- hemoglobin ≥8 g/dL
- total bilirubin ≤2 X institutional upper limit of normal (ULN)
- AST(SGOT) and ALT(SGPT) ≤3 X ULN
- creatinine clearance ≥30 mL/min (measured or calculated)
Patients are allowed to receive blood transfusions before receiving their first dose of ATN-224 to bring the hemoglobin level to ≥8 g/dL to meet eligibility criteria.
- Use of adequate contraception. The effects of ATN 224 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because antiangiogenic agents are known to be teratogenic, women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal and/or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation through the follow up visit 28 days after the last dose of ATN 224.
- Willingness to forego taking copper- or zinc-containing vitamins or supplements
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or thalidomide, lenalidomide, dexamethasone, arsenic trioxide, bortezomib, or glucocorticosteroids within 3 weeks prior to the first dose of ATN-224 or failure to recover from reversible adverse events due to agents administered previously
- Patients who cannot tolerate, based on previous experience, the assigned dose of bortezomib, including those with ≥ Grade 2 neuropathy
- Concurrent administration of any other investigational agents
- History of malabsorption syndromes or other gastrointestinal disorders that may affect ATN-224 absorption, including bowel obstruction, celiac disease, sprue, cystic fibrosis
- Ineligible to receive omeprazole (Prilosec® OTC) or other long-acting antacid
- Inability to swallow study medication capsules
- Not a suitable candidate in the opinion of the investigator for additional bortezomib therapy
- Other serious medical or psychiatric illness preventing informed consent or intensive treatment
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Women who are pregnant or lactating
- Known history of HIV
- History of another prior cancer, except basal cell carcinoma or carcinoma in situ of the cervix (or if there has been no evidence of recurrence for at least 5 years)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
ATN-224 + bortezomib
|
ATN-224 and bortezomib dose to be determined in Phase I portion of study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study
Time Frame: Ongoing
|
Ongoing
|
Phase II: Efficacy
Time Frame: End of Study
|
End of Study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase I: Preliminary evidence of efficacy
Time Frame: End of Study
|
End of Study
|
Phase II: progression-free survival and duration of response
Time Frame: End of Study
|
End of Study
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gilad Gordon, MD
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Chelating Agents
- Sequestering Agents
- Bortezomib
- Tetrathiomolybdate
Other Study ID Numbers
- ATN-224-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on ATN-224 + bortezomib
-
Peel Therapeutics IncRecruitingAdvanced Solid TumorUnited States
-
AblynxCompletedRheumatoid ArthritisUnited States, Russian Federation, Canada, Hungary, Japan, Serbia, South Africa, Switzerland
-
AblynxCompletedRheumatoid ArthritisJapan
-
AttenuonProstate Cancer Clinical Trials ConsortiumUnknown
-
Rubius TherapeuticsTerminatedNon Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast CancerUnited States
-
MedImmune LLCGlaxoSmithKlineCompleted
-
AmgenCompletedMultiple MyelomaUnited States, Australia
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsCompleted
-
AttenuonUnknown
-
DePuy OrthopaedicsCompletedFemoral Fracture (Proximal)United States